Test Our Integrated Precision Medicine Approach
Fee-for-service and collaboration
Continuous screening:
Turnaround time starts at day of arrival of compounds at Oncolines and ends with transfer of final report and primary data
Reporting:
Primary data and study report shared via a secured link
Achieve Reproducible Results and Short Timelines
via www.oncolines.com:
Proliferation assays and bioinformatics, drug combination studies and cell-based assays to determine mechanism of action
via www.residencetimer.com:
Biochemical assays to characterize the binding of drug candidates to the target; surface plasmon resonance (SPR) for binding kinetics, kinase activity screening, in vitro proof-of-concept studies